Pre-trabeculectomy intravitreal injections of bevacizumab for treating neovascular glaucoma in diabetic patients

Ivan Marjanović; Marjan Marjanović; Ranko  Gvozdenović; Marija Marjanović; Vujica Marković; Marija Božić; Vesna Marić; Antonio Martinez

doi:10.2298/VSP170531137M

Ivan Marjanović University of Belgrade, Faculty of Medicine, Clinical Center of Serbia, University Eye Clinic, Belgrade, Serbia
Marjan Marjanović University Business Academy, Faculty of Stomatology, Pančevo, Serbia
Ranko Gvozdenović Clinical Center of Serbia, University Eye Clinic, Belgrade, Serbia
Marija Marjanović University of Belgrade, Faculty of Medicine, Clinical Center of Serbia, Cardiology Clinic, Belgrade, Serbia
Vujica Marković University of Belgrade, Faculty of Medicine, Clinical Center of Serbia, University Eye Clinic, Belgrade, Serbia
Marija Božić University of Belgrade, Faculty of Medicine, Clinical Center of Serbia, University Eye Clinic, Belgrade, Serbia
Vesna Marić University of Belgrade, Faculty of Medicine, Clinical Center of Serbia, University Eye Clinic, Belgrade, Serbia
Antonio Martinez Science Research and Sports, C linical Research Department, Ames, La Coruna, Spain

DOI: https://doi.org/10.2298/VSP170531137M

Keywords: diabetes mellitus, glaucoma, neovascular, bevacizumab, mitomycin, trabeculectomy, treatment outcome

Abstract

Background/Aim. Neovascular glaucoma (NVG) is a secondary glaucoma caused by occlusion of the trabecular network of newly formed blood vessels. The aim of this study was to evaluate the efficacy and safety of intravitreal injections of bevacizumab before trabeculectomy with mitomycin C (MMC) for the treatment of NVG. Methods. A prospective and open-label study was conducted from May 2013 to December 2014 on consecutive NVG patients who underwent intravitreal injections of bevacizumab and a primary trabeculectomy with MMC. All patients were followed-up at least for 12 months. Success was defined as an intraocular pressure (IOP) of ≤ 21 mm Hg with or without topical ocular hypotensive medication. Results. Fourteen eyes of 12 diabetic patients fulfilled the respective demands of the inclusion and exclusion criteria. The mean (± standard deviation) follow-up period was 15.0 (± 2.0) months (range, 12 to 19 months). After one year of follow-up, 11 (78.6%) eyes had an IOP ≤ 21 mmHg. The mean IOP was significantly reduced from 42.4 (± 9.7) mmHg preoperatively to 18.4 (± 2.9) mmHg postoperatively (p < 0.0001). Regarding surgical complications, 6 months of trabeculectomy, hyphaema was observed in 3 (21.4%) eyes, macular edema in one (7.1%) eye and recurrence of neovascularization requiring intravitreal bevacizumab injection in 2 (14.2%) eyes. Conclusion. Preoperative intravitreal bevacizumab may be effective as adjunctive treatment for trabeculectomy with mitomycin-C for neovascular glaucoma patients.

Author Biography

Ranko Gvozdenović, Clinical Center of Serbia, University Eye Clinic, Belgrade, Serbia

Doktor Medicine

References

Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108(10): 1767–76; quiz 1777, 1800.

Rulli E, Biagioli E, Riva I, Gambirasio G, De Simone I, Floriani I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol 2013; 131(12): 1573–82.

Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. In-travitreal bevacizumab (Avastin) in the treatment of neovas-cular glaucoma. Am J Ophthalmol 2006; 142(6): 1054–6.

Yoshida N, Hisatomi T, Ikeda Y, Kohno R, Murakami Y, Imaki H, et al. Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy speci-mens. Graefes Arch Clin Exp Ophthalmol 2011; 249(10): 1547–52.

Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26(3): 275–8.

Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26(3): 279–84.

Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris ne-ovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Oph-thalmol 2006; 142(1): 155–8.

Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovasculariza-tion and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115(9): 1571–80, 1580.e1–3.

Marey HM, Ellakwa AF. Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of ne-ovascular glaucoma. Clin Ophthalmol 2011; 5: 841–5.

Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S. Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica 2006; 220(6): 383–8.

Elmekawey H, Khafagy A. Intracameral ranibizumab and subse-quent mitomycin C augmented trabeculectomy in neovascular glaucoma. J Glaucoma 2014; 23(7): 437–40.